Literature DB >> 31419656

A multifunctional lipid that forms contrast-agent liposomes with dual-control release capabilities for precise MRI-guided drug delivery.

Chenyu Liu1, Kai K Ewert2, Ning Wang3, Youli Li4, Cyrus R Safinya5, Weihong Qiao6.   

Abstract

Monitoring of nanoparticle-based therapy in vivo and controlled drug release are urgently needed for the precise treatment of disease. We have synthesized a multifunctional Gd-DTPA-ONB (GDO) lipid by introducing the Gd-DTPA contrast agent moiety into an o-nitro-benzyl ester lipid. By design, liposomes formed from the GDO lipid combine MRI tracking ability and dual-trigger release capabilities with maximum sensitivity (because all lipids bear the cleavable moiety) without reducing the drug encapsulation rate. We first confirmed that both photo-treatment and pH-triggered hydrolysis are able to cleave the GDO lipid and lyse GDO liposomes. We then investigated the efficiency of drug release via the combined release processes for GDO liposomes loaded with doxorubicin (DOX). Relative to neutral pH, the release efficiency in acidic environment increased by 10.4% (at pH = 6.5) and 13.3% (at pH = 4.2). This pH-dependent release response is conducive to distinguishing pathological tissue such as tumors and endolysosomal compartments. The photo-induced release efficiency increases with illumination time as well as with distance of the pH from neutral. Photolysis increased the release efficiency by 13.8% at pH = 4.2, which is remarkable considering the already increased amount of drug release in the acidic environment. In addition, the relaxation time of GDO liposomes was 4.1 times that of clinical Gd-DTPA, with brighter T1-weighted imaging in vitro and in vivo. Real-time MRI imaging and in vivo fluorescence experiments demonstrated tumor targeting and MRI guided release. Furthermore, significant tumor growth inhibition in a treatment experiment using DOX-loaded GDO liposomes clearly demonstrated the benefit of photo-treatment for efficacy: the tumor size in the photo-treatment group was 3.7 times smaller than in the control group. The present study thus highlights the benefit of the design idea of combining efficient imaging/guiding, targeting, and triggerable release functions in one lipid molecule for drug delivery applications.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer therapy; Contrast-agent liposomes; Dual-control release; MRI-Guided drug delivery; Nanoparticles

Mesh:

Substances:

Year:  2019        PMID: 31419656     DOI: 10.1016/j.biomaterials.2019.119412

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  10 in total

1.  Research on the Construction of Bispecific-Targeted Sustained-Release Drug-Delivery Microspheres and Their Function in Treatment of Hepatocellular Carcinoma.

Authors:  Zi Li Huang; Feng Li; Jun Tao Zhang; Xiang Jun Shi; Yong Hua Xu; Xiu Yan Huang
Journal:  ACS Omega       Date:  2022-06-13

Review 2.  Targeting drug delivery with light: A highly focused approach.

Authors:  Teresa L Rapp; Cole A DeForest
Journal:  Adv Drug Deliv Rev       Date:  2021-01-22       Impact factor: 15.470

3.  Sustained Release of Melatonin from GelMA Liposomes Reduced Osteoblast Apoptosis and Improved Implant Osseointegration in Osteoporosis.

Authors:  Long Xiao; Jiayi Lin; Ruoyu Chen; Yu Huang; Yu Liu; Jiaxiang Bai; Gaoran Ge; Xiaopeng Shi; Yong Chen; Jiandong Shi; Lu Aiqing; Huilin Yang; Dechun Geng; Zhirong Wang
Journal:  Oxid Med Cell Longev       Date:  2020-05-28       Impact factor: 6.543

4.  Engineering Tumor-Targeting Nanoparticles as Vehicles for Precision Nanomedicine.

Authors:  Amber Gonda; Nanxia Zhao; Jay V Shah; Hannah R Calvelli; Harini Kantamneni; Nicola L Francis; Vidya Ganapathy
Journal:  Med One       Date:  2019-09-30

Review 5.  Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery.

Authors:  Bethany Almeida; Okhil K Nag; Katherine E Rogers; James B Delehanty
Journal:  Molecules       Date:  2020-12-01       Impact factor: 4.411

6.  MR-labelled liposomes and focused ultrasound for spatiotemporally controlled drug release in triple negative breast cancers in mice.

Authors:  Maral Amrahli; Miguel Centelles; Paul Cressey; Martynas Prusevicius; Wladyslaw Gedroyc; Xiao Yun Xu; Po-Wah So; Michael Wright; Maya Thanou
Journal:  Nanotheranostics       Date:  2021-01-01

Review 7.  Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.

Authors:  Fan-Hua Kong; Qi-Fa Ye; Xiong-Ying Miao; Xi Liu; Si-Qi Huang; Li Xiong; Yu Wen; Zi-Jian Zhang
Journal:  Theranostics       Date:  2021-03-13       Impact factor: 11.556

8.  Effects of Docetaxel Injection and Docetaxel Micelles on the Intestinal Barrier and Intestinal Microbiota.

Authors:  Qingya Liu; Yi Lu; Yao Xiao; Liping Yuan; Danrong Hu; Ying Hao; Ruxia Han; Jinrong Peng; Zhiyong Qian
Journal:  Adv Sci (Weinh)       Date:  2021-10-28       Impact factor: 16.806

Review 9.  Recent Advances in Functionalized Nanoparticles in Cancer Theranostics.

Authors:  Sarkar Siddique; James C L Chow
Journal:  Nanomaterials (Basel)       Date:  2022-08-17       Impact factor: 5.719

10.  The Value of Convolutional Neural Network-Based Magnetic Resonance Imaging Image Segmentation Algorithm to Guide Targeted Controlled Release of Doxorubicin Nanopreparation.

Authors:  Hujun Liu; Hui Gao; Fei Jia
Journal:  Contrast Media Mol Imaging       Date:  2021-07-26       Impact factor: 3.161

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.